Compare ARK Genomic Revolution ETF (ARKG) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Wendys Co — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Wendys Co trades at $7.52 (market cap $1.44B). The key difference: Wendys Co pays a 7.41% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Wendys Co nearer its low. Which is the better fit depends on your goals.
| ARKG | WEN | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $11.33 |
52-Week Low | $23.09 | $6.17 |
Market Cap | — | $1.44B |
Enterprise Value | — | $5.26B |
Dividend Yield | — | 7.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Wendy's (WEN) trades at $7.55, down 0.53% on the day, amid mixed technical signals with a bullish overall trend but neutral oscillators. The stock shows attractive valuation metrics with a P/E of 9.82 and P/S of 0.66, though net income margins have declined from 9.37% in 2023 to 6.77% in 2026. Recent earnings beats and a 7.1% dividend yield provide support, while meme stock volatility and competitive pressures create uncertainty.
The outlook balances value appeal against growth challenges. Positive factors include consistent earnings beats, strong ROE of 120.88%, and analyst consensus price target of $7.96 offering 5.4% upside. Risks include declining profitability, high debt levels (debt-to-asset ratio of 55.68%), and reliance on meme-driven momentum rather than fundamental improvement for recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
